v3.25.4
Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives - Costs - Footnotes (Detail) - USD ($)
$ in Millions
3 Months Ended 12 Months Ended 21 Months Ended 27 Months Ended
Dec. 14, 2023
Dec. 31, 2023
Dec. 31, 2025
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2025
Dec. 31, 2025
Restructuring Cost and Reserve [Line Items]              
Restructuring charge (credit) [1]     $ 1,092 $ 1,987 $ 1,968    
Seagen [Member]              
Restructuring Cost and Reserve [Line Items]              
Post closing compensation expense $ 476            
Seagen [Member] | Restructuring Charges and Acquisition-Related Costs [Member]              
Restructuring Cost and Reserve [Line Items]              
Post closing compensation expense   $ 476          
Biopharma [Member]              
Restructuring Cost and Reserve [Line Items]              
Restructuring charge (credit)     691 1,800 1,500    
Biopharma [Member] | Manufacturing Optimization Program [Member]              
Restructuring Cost and Reserve [Line Items]              
Restructuring charge (credit)     (288) 1,200   $ 875  
Biopharma [Member] | Realigning Our Cost Base Program [Member]              
Restructuring Cost and Reserve [Line Items]              
Restructuring charge (credit)     $ 920 $ 571 1,400   $ 2,900
Biopharma [Member] | Transforming to a More Focused Company Plan [Member]              
Restructuring Cost and Reserve [Line Items]              
Restructuring charge (credit)         $ 3    
[1] Primarily represents cost-reduction initiatives. Amounts associated with our Biopharma segment: (i) charges of $691 million for 2025 (including charges of $920 million for our Realigning our Cost Base Program and credits of $288 million for our Manufacturing Optimization Program), (ii) charges of $1.8 billion for 2024 (including charges of $1.2 billion our Manufacturing Optimization Program and charges of $571 million for our Realigning our Cost Base Program) and (iii) charges of $1.5 billion for 2023 (including charges of $1.4 billion for our Realigning our Cost Base Program and charges of $3 million for our Transforming to a More Focused Company program, that we have substantially completed). For 2025 and 2024, Employee terminations include revisions of estimates of previously recorded accruals for severance benefits, driven in large part by higher-than-expected voluntary attrition.